Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Trading Up 4.6 %

Minerva Neurosciences stock opened at $2.05 on Friday. The business’s fifty day simple moving average is $2.23 and its two-hundred day simple moving average is $2.47. Minerva Neurosciences has a 12 month low of $1.90 and a 12 month high of $10.18. The company has a market capitalization of $14.33 million, a price-to-earnings ratio of -4.66 and a beta of 0.12.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.